Status:
RECRUITING
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Lead Sponsor:
Seoul National University Hospital
Conditions:
Cancer of Breast
Trastuzumab Emtansine
Eligibility:
All Genders
19+ years
Brief Summary
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Eligibility Criteria
Inclusion
- HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer
- Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting
- Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression
Exclusion
- Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)
- Has been previously treated with T-DM1 for advanced breast cancer
- Has been previously treated with 4 or more lines of therapy for advanced breast cancer
- Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).
Key Trial Info
Start Date :
February 26 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2029
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06928818
Start Date
February 26 2025
End Date
September 30 2029
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080